Please login to the form below

Not currently logged in
Email:
Password:

Larry Bell joins Dutch biopharma Prosensa

Takes up role as head of global regulatory affairs

Prosena Larry BellDutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs.

He joins the Leiden-based company with more than 18 years of regulatory affairs experience gained at companies that include Merck, Bristol-Myers Squibb, Aventis and Amgen.

Prior to setting up his own consultancy, his most recent role was as vice president and global head of regulatory affairs at GE Healthcare

For his new role at Prosensa, which focuses on RNA-modulating therapeutics for rare diseases with high unmet need, Bell will be based in the US and oversee the company's global regulatory activities.

Bell said: “This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them.

“I look forward to helping progress Prosensa's cutting-edge therapies through the regulatory process.”

18th February 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics